Pfizer is the largest shareholder of Alzheimer's drug developer Cortexyme, which has filed to raise up to $86.3m in its initial public offering.
Cortexyme, a US-based Alzheimer’s disease drug developer, has filed for an $86.3m initial public offering on the Nasdaq Global Market that will enable corporates Alphabet, Pfizer and Takeda to exit.
Founded in 2012, Cortexyme is working on therapeutics to treat Alzheimer’s and other degenerative diseases. Its approach focuses on the presence of a pathogenic bacterium called porphyromonas gingivalis in the brains of Alzheimer’s patients.
The IPO proceeds will support a phase 2/3 trial for the company’s lead product candidate,…
